Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

AI in Bio Pharmaceuticals Market Analysis Report 2022 Featuring Insilico Medicine, Cyclica, Microsoft, Tencent, Amgen, Mila, NVIDIA, Pfizer, GSK, KNIME, Google

Published

on

Dublin, May 12, 2022 (GLOBE NEWSWIRE) — The “AI in Bio Pharmaceuticals” report has been added to ResearchAndMarkets.com’s offering.

This report forecasts a considerable trend for “AI democratization” where various machine learning/deep learning technologies become available in pre-trained, pre-configured “off-the-shelf” formats, or relatively ready-to-use formats – via cloud-based models, frameworks, and drag-and-drop AI-pipeline building platforms (for example, KNIME), companies, like Google, Tencent, Nvidia, Microsoft, and others, are expanding into healthcare space via not only offering specialized services and tools to pharma counterparties but also directly investing into biotech start-ups and larger companies, creating own centres of excellence and commercial subsidiaries with focus on Life Sciences.

AI is regarded by some top executives at big pharma (Novartis, Pfizer, GSK and others) as a tool to uncover not only new molecules but also new targets. The ability of deep neural networks to build ontologies from multimodal data (e.g., “omics” data) is believed to be among the most disruptive areas for AI in drug discovery, alongside data mining from unstructured data, like text (using natural language processing, NLP).

In this report, the use of artificial intelligence or any other computational algorithm for drug discovery, biomarker development, and advanced R&D is highlighted along with technology providers in pharma industry, computational methods used by the most advanced AI companies, an overall growth of investment and business development activity in the area of pharmaceutical AI along with some other sections which are listed in the table of content of the report.

The technology providers in Pharmaceutical Industry are profiled in the report into 6 categories: Artificial Intelligence (R&D Platforms), Quantum Computing, Supporting Services, “Big Tech” Corporations, Autonomous Labs, and Big Data Providers.

The publisher has also highlighted certain challenges which are faced by the pharma sector during drug discovery and the solutions that could be implemented.

A new drug takes an average of ten years to reach the market. According to Tufts University’s Center for the Study of Medicine Development (CSDD), the cost of producing a new prescription drug that receives FDA clearance is around $2.6 billion as of 2014. The pharmaceutical industry is reaching the end of its life cycle, and the returns on new treatments that do make it to market no longer justify the vast investments that pharma makes in R&D.

Notable AI Breakthroughs:

  • Insilico Medicine announces the preclinical candidate for kidney fibrosis discovered using end-to-end Artificial Intelligence engine. The preclinical candidate has the desirable pharmacological properties, pharmacokinetic pro?le and demonstrated auspicious results in in-vitro and in-vivo preclinical studies. (Feb 2021)
  • Cyclica launched an AI-based drug discovery platform that achieved over 60% of actionable hits for its pharma clients. Cyclica has partnered with over 100 global pharma and biotech companies and academia across many therapy areas. These partnerships have resulted in 64% of programmes resulting in actionable hits. (March 2021)

Recent Key Activities (Big-Tech Companies expanding in the domain)

  • Microsoft Cloud for healthcare brings together trusted capabilities to customers and partners that enhance patient engagement, empower health team collaboration, and improve clinical and operational data insights to improve decision-making and operational efficiencies
  • Tencent is entering pharma and healthcare space with a focus on AI-based platforms for analysis of research and clinical data. Also, it promotes innovations in hospitals via the digitalization of medical services and pharmaceutical supply chains. It also unites one of the largest online communities of doctors and providers for telemedicine services

Recent Developments

  • In May 2021, Microsoft partnered with robotic surgery startup Cmr Surgical on a proof of concept to store clinical data from cmr’s next-generation surgical robot, Versius, into a glass, marking an exciting step-change for the future of health data. Rich data from hundreds of surgical robotic procedures can be stored safely and securely into one Microsoft project silica glass platter and could ultimately be harnessed to improve patient outcomes. Also, Microsoft participated (via m12) in the $21.5m series A round for lab automation startup artificial
  • In March 2021, Amgen announced that it has entered into a multi-year partnership with Mila – Quebec Artificial Intelligence Institute
  • In April 2021, NVIDIA announced a strategic partnership with Schrodinger to expand the speed and accuracy of Schrodinger’s computational drug discovery platform and enable rapid, accurate evaluation of billions of molecules for the potential development of therapeutics

Critical Questions the Report Answers:

  • What are the technological advancements of artificial intelligence in the pharma industry by key players?
  • What are the notable technological evolutions of top players?
  • What are the challenges faced by pharma industry and how they have been addressed using artificial intelligence?
  • What are the applications and use cases for AI in advanced R&D?
  • What are the most used computational methods for AI?
  • Who are the top publicly traded companies in the domain?
  • What are the recent investments, deals, and collaboration for AI in pharma?
  • What is the geographical presence of AI for the pharma industry?

Key Topics Covered:

1. Introduction & Overview
1.1. The Pharma Industry’s Increasing Influence of Technology Providers
1.2. Selected Industry Developments: Overview (Pharma)
1.3. Recent advances in the drug AI industry
1.4. Companies Working Around Different Applications of AI In Pharmaceuticals

2. Executive Summary
2.1. Big Pharma’s’ AI-focused partnerships
2.2. Key Business Takeaways
2.3. Key Technology Takeaways
2.4. AI in the Global Context

3. Technology Landscape
3.1. Technology Evolution of Few Key Players
3.2. Key challenges of Pharma industry and how are they addressed
3.3. Case Studies: Technology Providers in Pharma Industry
3.4. AI for Advanced R&D: Applications and Use Cases
3.4.1. Significant Research and Development Use Cases of AI Application in Biopharma
3.5. Computational Methods employed by the Most Advanced AI Companies

4. Competitive Landscape
4.1. Investment, Deals & Collaborations
4.2. Leading Companies & Investors in Pharmaceutical AI
4.3. Top Publicly Traded Companies in the AI-Pharma Industry

5. Business Overview
5.1. New Business Models incorporating technological advancements
5.2. Investment and Funding Details
5.3. Geographical Presence: AI for Drug Discovery

6. Key Take-aways

Companies Mentioned

  • Insilico Medicine
  • Cyclica
  • Microsoft
  • Tencent
  • Amgen
  • Mila – Quebec Artificial Intelligence Institute
  • NVIDIA
  • Pfizer
  • GSK
  • KNIME
  • Google

For more information about this report visit https://www.researchandmarkets.com/r/pe5n8t


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending